Thermo Fisher Scientific has received emergency use authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit from the US Food and Drug Administration (FDA).
The polymerase chain reaction (PCR) test has been designed for detecting non-variola Orthopox viruses, including the monkeypox virus, in nearly three-and-a-half hours.
Go deeper with GlobalData
It is developed to detect DNA from the monkeypox virus (clade I/II) and screen for non-variola Orthopoxviruses in human lesion swab samples collected from people suspected of monkeypox infection.
The company stated that positive test results indicate the presence of DNA from the monkeypox virus or other non-variola orthopoxviruses.
Clinicians need to correlate PCR results with patient history, as well as other diagnostic data for determining the status of the infection.
See Also:
Thermo Fisher Scientific Genetic Testing Solutions senior medical director Manoj Gandhi said: “Ensuring that all US laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“This helps expedite the availability of results so that patients can receive the appropriate treatment quickly.
“Authorised testing also enables public health agencies to stay one step ahead of the virus by monitoring the viral spread and addressing affected populations accordingly.”
The regulatory approval of the TaqPath Monkeypox/Orthopox Virus DNA Kit reflects the company’s commitment to developing diagnostic tools to address the demanding public health emergencies as early as possible.
Last month, Thermo Fisher Scientific signed a definitive agreement to buy global speciality diagnostics company, The Binding Site Group, in a cash transaction valued at $2.6bn.
The Binding Site Group is engaged in the research, development, manufacture as well as distribution of assays used for detecting cancers and immune disorders.
